Participation notification by UBS Group AG Press release Regulated information Brussels, December 4, 2025, 17:45 CET In line with Belgian transparency legislation (Law of May 2, 2007), UBS Group AG recently sent to Solvay the following transparency notification indicating that they crossed the threshold of 3%. Here is a summary of the notification: Date on which the threshold was crossedVoting rights after the transactionEquivalent financial instruments after the transactionTotalNovember 27, 20250.17%2.88%3.05% The notific...
Notification de participation par UBS Group AG Communiqué de presse Information réglementée Bruxelles, le 4 décembre 2025 - 17h45 CET Conformément à la législation et réglementation en matière de transparence financière (loi du 2 mai 2007), UBS Group AG a envoyé récemment à Solvay la notification de transparence suivante, indiquant avoir franchi le seuil de 3%. Voici un résumé de la notification: Date à laquelle le seuil a été franchi Droits de vote après la transaction Instruments financiers é...
Participatiemelding van UBS Group AG Persbericht Gereglementeerde informatie Brussel, 4 december 2025 - 17u45 CET In overeenstemming met de Belgische transparantiewetgeving (Wet van 2 mei 2007) heeft UBS Group AG onlangs de volgende transparantiekennisgeving naar Solvay gestuurd om aan te geven dat ze de drempel van 3% heeft overschreden. Hier is een samenvatting van de beweging: Datum van drempeloverschrijdingStemrechten na de transactieAan stemrechten gelijkgestelde financiële instrumenten na de transactieTotaal27 novembe...
Communiqué de presse : Sanofi finalise l’acquisition de Vicebio Sanofi finalise l’acquisition de Vicebio Paris, le 4 décembre 2025. Sanofi annonce aujourd’hui la finalisation de . Cette acquisition apporte à Sanofi un candidat-vaccin combiné en phase précoce de développement contre le virus respiratoire syncytial (VRS) et le métapneumovirus humain (HMPV), deux virus respiratoires, et renforce les capacités de conception et de développement de vaccins grâce à la technologie « Molecular Clamp » de Vicebio. Le candidat-vaccin acquis complète la position de Sanofi dans le domaine des vaccins ...
Press Release: Sanofi completes acquisition of Vicebio Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its . This acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology. The acquired vaccine candidate complements Sanofi’s position in respiratory vaccines. It enables Sanofi to offer increased physician and patient choice in...
A director at Heidelberg Materials AG sold 560,573 shares at 221.256EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Heineken Holding N.V. reports transactions under its current share buyback programme Heineken Holding N.V. reports transactions under its current share buyback programme Amsterdam, 1 December 2025 - Heineken Holding N.V. (EURONEXT:HEIO; OTCQX: HKHHY), hereby reports transaction details related to the first tranche of up to circa €375 million tranche of its share buyback programme of up to circa €750 million as communicated on 12 February 2025. From 24 November 2025 up to and including 28 November 2025 a total of 179,389 shares were repurchased on exchange at an average price of € 61.25. ...
A director at Adecco Group AG bought 4,000 shares at 22.180CHF and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatmentDupixent, which i...
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU wh...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.